Tirzepatide 20mg About This Product
Tirzepatide peptide is a synthetic dual agonist developed for research purposes. It is composed of a 39-amino acid sequence, specifically designed to target both the GIP and GLP-1 receptors. Tirzepatide has a molecular weight of approximately 4810.52 g/mol and includes a C20 fatty diacid chain that extends its circulation time in research settings.
Tirzepatide 20mg is provided in a lyophilized powder format, which helps maintain stability during storage and transport. The 20mg vial is typically used for mid-range dosing in studies involving metabolic regulation, glucose signaling, and incretin biology. Those who wish to buy tirzepatide with this dosage can reach out to Med Supply Solutions for more information.
Tirzepatide 20mg Key Features and Benefits
- High Purity: Verified ≥99% purity through HPLC/MS with certificates of analysis.
- Dual Agonist Profile: Activates both GIP and GLP-1 receptors, allowing for studies on metabolic and endocrine responses.
- Extended Half-Life: The C20 fatty diacid chain prolongs its presence in the system, supporting once-weekly dosing protocols in research studies.
- Lyophilized Stability: Freeze-dried format ensures long-term storage at low temperatures and easy reconstitution for experiments.
- Reproducibility in Research: Reliable dosing in both in vitro and in vivo studies focused on metabolic pathways, glucose regulation, and energy balance.
- For Laboratory Research Use Only: Not for human or veterinary use.
Tirzepatide 20mg Mechanism & Research Applications
Tirzepatide functions as a dual agonist peptide, primarily activating the GIP and GLP-1 receptors involved in metabolic signaling. It is used in research to explore how this dual activation can influence glucose levels, appetite regulation, and energy utilization.
Research on tirzepatide has focused on its effects on insulin secretion, glucagon suppression, and gastric emptying. Studies also investigate how this dual receptor activation affects lipid metabolism, body composition, and hormonal regulation. Tirzepatide’s ability to engage two pathways simultaneously makes it a unique tool for exploring the integration of metabolic systems.
These research applications aim to provide deeper insights into the peptide’s role in metabolic health and physiological regulation.
Tirzepatide 20mg Dosing & Observed Effects in Research
Published studies often use dose-escalation protocols to observe tirzepatide’s behavior in both preclinical and early-phase clinical settings. Initial dosing generally begins at 2.5 mg weekly, with subsequent increases of 2.5 mg every 4 weeks to achieve maintenance doses, typically reaching 10 mg or 15 mg weekly.
In animal models, tirzepatide is studied across various doses, ranging from 1 mg to 12 mg per week. The 10 mg peptide is a common mid-range dosing option used to investigate dose-dependent effects on glucose regulation, energy balance, and metabolic biomarkers. Research results show a dose-dependent suppression of food intake, reduction in body weight, and improvement in glucose tolerance, with linear dose-response relationships.
Tirzepatide 20mg is particularly useful for studies that require observing the effects of higher dosing levels and extended exposure periods.
Tirzepatide 20mg Storage, Safety & References
- Primary Storage: Tirzepatide lyophilized peptide should be stored refrigerated at 2–8°C (36–46°F) in its original container, protected from light. This is the manufacturer-recommended primary storage method for maintaining long-term stability.
- Short-Term Room Temperature: Tirzepatide can be stored temporarily at room temperature (not exceeding 30°C / 86°F) for up to 21 days only. Beyond this period, potency degradation increases significantly.
- After Reconstitution: Store reconstituted tirzepatide at 2–8°C (36–46°F) and use within 7–14 days depending on the reconstitution buffer and formulation. Do not freeze reconstituted solutions, as freeze-thaw cycles cause peptide degradation.
Important: Tirzepatide should NOT be frozen at -20°C or stored in freezer compartments, as freezing causes peptide structure degradation and loss of potency.
References
https://pubmed.ncbi.nlm.nih.gov/32730231
https://pmc.ncbi.nlm.nih.gov/articles/PMC10362946
https://www.science.org/doi/10.1126/sciadv.adu1589
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000PharmR.pdf
https://www.pnas.org/doi/10.1073/pnas.2116506119
Compliance Notice
This product is intended for laboratory research use only and is not approved for human or veterinary use. Researchers planning to use this product in animal studies should ensure compliance with IACUC guidelines and institutional research protocols.